At the annual congress of the European Society for Medical Oncology (ESMO), Seagen (Nasdaq: SGEN) and Astellas Pharma (TYO: 4503) have presented detailed data from the Phase III EV-302 study.
Top-line data from the trial were released in late September 2023.
Also known as KEYNOTE-A39, the study is testing a combination of Seagen's Padcev (enfortumab vedotin-ejfv) and Merck's Keytruda (pembrolizumab), for certain people with urothelial cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze